Lisata Therapeutics
LSTA
21 hedge funds and large institutions have $2.3M invested in Lisata Therapeutics in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 2 closing their positions.
13% more capital invested
Capital invested by funds: $2.03M → $2.3M (+$271K)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
0.26% less ownership
Funds ownership: 9.15% → 8.89% (-0.26%)
5% less funds holding
Funds holding: 22 → 21 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$43.9K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$34.6K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14K |
| 4 |
Renaissance Technologies
New York
|
+$6.81K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.84K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$68.2K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$38.6K |
| 3 |
Morgan Stanley
New York
|
-$7.55K |
| 4 |
BlackRock
New York
|
-$702 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$696 |
LSTA Hedge Fund Activity: Q1 2024 in Review
21 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q1 2024, worth a combined $2.3M — up 13% from $2.03M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LSTA and 1 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 6 added.
The largest buyer was BML Capital Management, adding an estimated $43.9K. The largest seller was Susquehanna International Group, cutting an estimated $68.2K.
- 21 institutional investors held Lisata Therapeutics (LSTA) as of Q1 2024, down from 22 in Q4 2023.
- Funds reported $2.3M of Lisata Therapeutics stock for Q1 2024, up 13% quarter-over-quarter.
- 1 fund opened new Lisata Therapeutics positions in Q1 2024 and 2 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q1 2024 was BML Capital Management, an estimated $43.9K added.
- The largest Lisata Therapeutics seller in Q1 2024 was Susquehanna International Group, an estimated $68.2K sold.
Based on aggregated 13F filings for Q1 2024.